Ficlatuzumab's Phase 3 advancement in head and neck squamous cell carcinoma — the AVEO Pharmaceuticals humanized IgG1 monoclonal antibody targeting HGF with picomolar affinity and nanomolar potency, currently enrolling patients in the FIERCE-HN trial for recurrent/metastatic HPV-negative HNSCC in combination with cetuximab — represents the most clinically advanced HGF-targeting...